Antibacterial agents active against Gram Negative Bacilli in phase I, II, or III clinical trials

“Antibacterial agents active against Gram‑Negative Bacilli in Phase I, II, or III Clinical Trials,” by David L. Paterson, surveys nearly 50 investigational therapeutics—28 small‑molecule antibiotics and 21 non‑traditional modalities—now in the clinic. The review highlights both the promise of this pipeline and the obstacles that remain, including toxicity‑related attrition, funding gaps for pivotal Phase III studies in high‑mortality indications such as ventilator‑associated pneumonia, and the developmental […]
Outstanding Scientific Research Award for Omnix Medical’s novel OMN51

We’re thrilled to share that Omnix Medical’s research, in collaboration with Dr. Heching, the Adult Cystic Fibrosis and Bronchiectasis Clinic Director at Beilinson-Rabin Medical Center, has been awarded the prestigious award for Outstanding Scientific Research at the 2024 North American Israeli Pulmonary Alliance (NAIPAC) Conference in Jerusalem. The work, which summarizes a one-year study evaluating […]
Omnix Medical Granted Fast-Track Designation by U.S. FDA for its Next-Generation Anti-Infective OMN6

Designation underlines the need for novel, first-in-class antimicrobials for the treatment of infections with Gram-negative bacteria Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the Company has received fast-track designation for its novel anti-infective OMN6 from the U.S. Food and Drug Administration (FDA). Fast track expedited […]
Omnix Medical Receives U.S. FDA Approval of a Phase II Trial of its Next-Generation Anti-Infective OMN6

JERUSALEM, Israel, November 20, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced that the U.S. Food and Drug Administration (FDA) has approved a planned Phase II trial of the Company´s novel anti-infective OMN6. The multinational, multicenter trial will assess the safety and pharmacokinetics of OMN6 […]
OMN6 – Omnix Medical’s Lead Antimicrobial Peptide Receives Notice of Allowance from the Indian Patent Office

We are here to announce that the Indian Patent Office has issued a Notice of Allowance for Omnix Medical’s lead antimicrobial peptide for the treatment of infectious diseases. This pivotal achievement signifies that OMN6, developed with a commitment to revolutionize infectious disease treatment, has met the stringent criteria required for intellectual property protection. Importantly, the […]
Omnix Medical Announces Excellent Topline Data from the Phase I Clinical Trial of its Novel Anti-Infective OMN6

OMN6 demonstrates safety and tolerability at clinically significant dose levels JERUSALEM, Israel, May 8th, 2023 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced positive top-line results from the Phase I clinical trial of its lead compound OMN6, an anti-infective with a completely novel mechanism of action. […]
RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY

We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising […]
OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70

Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70. At Omnix, we are working hard to build our clinical pipeline with new peptide-based drugs that address broad unmet medical needs. Using Omnix drug discovery platform to screen a wide-ranging array of peptides originating from marine organisms, insects […]
OMNIX MEDICAL STARTS PHASE I CLINICAL TRIAL OF NOVEL ANTI-INFECTIVE; FIRST HEALTHY VOLUNTEERS DOSED

New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April 12, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since […]
OMNIX MEDICAL ADVANCES NOVEL ANTI-INFECTIVE PROGRAM INTO CLINICAL DEVELOPMENT

Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy […]